PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea flag South Korea · Delayed Price · Currency is KRW
413,500
+22,500 (5.75%)
Aug 20, 2026, 3:30 PM KST

PharmaResearch Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
176,522165,12192,04376,55140,57746,689
Depreciation & Amortization
16,23515,81513,64511,99610,6029,552
Loss (Gain) From Sale of Assets
-3.63162.1411.92-36.115,846-229.6
Asset Writedown & Restructuring Costs
1,3941,394-3,120-839.66
Loss (Gain) From Sale of Investments
-4,061-1,72920,191-3,0422,259-943.49
Loss (Gain) on Equity Investments
-643.74-425.47-5,954-680.032,192-556.93
Stock-Based Compensation
-149.42658.9657.1505.88-
Provision & Write-off of Bad Debts
65.73452.14-244.35582.21290.45-406.73
Other Operating Activities
31,31926,87917,3856,5127,5981,932
Change in Accounts Receivable
-11,868-4,445-8,535717.13-4,843-3,842
Change in Inventory
-32,217-26,249-11,940-28,188-8,3742,927
Change in Accounts Payable
8,019169.167,724-559.07597.78397.75
Change in Unearned Revenue
-39.03-7.9472.116.3211.36-
Change in Income Taxes
----9.631.52
Change in Other Net Operating Assets
-5,8175,87613,063-3,2302,1319,088
Operating Cash Flow
178,904183,162138,12264,94559,40465,297
Operating Cash Flow Growth
28.79%32.61%112.67%9.33%-9.03%101.59%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-28,997-29,727-36,415-12,063-17,257-20,645
Sale of Property, Plant & Equipment
225.23179.730.6828.65734.02-
Cash Acquisitions
-----35.01-
Sale (Purchase) of Intangibles
-1,741-4,877-2,310-623.05-460.83-2,786
Investment in Securities
-79,059-125,081-179,213-31,8605,446-66,427
Other Investing Activities
-15.66-82.432,507-522.63-794.6-590.91
Investing Cash Flow
-104,845-155,918-225,538-44,668-11,908-93,755

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--10,782--50,000
Total Debt Issued
--10,782--50,000
Short-Term Debt Repaid
-----860-29.13
Long-Term Debt Repaid
--3,370-17,946-18,799-2,126-1,976
Total Debt Repaid
-6,353-3,370-17,946-18,799-2,986-2,005
Net Debt Issued (Repaid)
-6,353-3,370-7,164-18,799-2,98647,995
Issuance of Common Stock
---359.24--
Dividends Paid
-11,729-11,729-10,090-7,529-6,316-5,030
Other Financing Activities
-80.37-174-102.45-0--0
Financing Cash Flow
-18,162-15,273182,643-25,969-9,30142,965

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1,653-1,6571,1184.41-76.12300.33
Miscellaneous Cash Flow Adjustments
-0-01,7580-6,862151.51
Net Cash Flow
57,54910,31598,103-5,68731,25714,959

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
149,907153,435101,70752,88342,14744,652
Free Cash Flow Growth
53.27%50.86%92.33%25.47%-5.61%-
Free Cash Flow Margin
26.51%28.61%29.05%20.26%21.64%28.98%
Free Cash Flow Per Share
12961.8213266.869879.605008.314224.854441.83
Levered Free Cash Flow
135,768109,27067,22521,15325,11527,225
Unlevered Free Cash Flow
142,198115,76570,12123,02027,50928,046

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
89.22,182428.67493.61159.45196.15
Cash Income Tax Paid
46,60639,61619,81116,96213,79810,051
Change in Working Capital
-41,922-24,657384.04-30,714-10,4678,421